8-K: Humana Reports Q4 Loss, Issues Lowered 2024 Guidance Amid Rising Medical Costs

Humana reported a fourth-quarter loss and provided a lower-than-expected initial full-year 2024 financial guidance, citing increased Medicare Advantage medical costs.

Summary

• Humana reported a GAAP loss per share of $4.42 for the fourth quarter of 2023, and an adjusted loss per share of $0.11.
• Full year 2023 earnings per share were $20.00 on a GAAP basis and $26.09 on an adjusted basis.
• The company's fourth-quarter results were impacted by higher-than-anticipated Medicare Advantage medical costs, particularly in inpatient utilization during November and December.
• Humana has issued initial full-year 2024 EPS guidance of approximately $14.87 on a GAAP basis and approximately $16.00 on an adjusted basis, assuming the higher medical costs persist.
• The company affirms its 2024 individual Medicare Advantage annual membership growth of approximately 100,000 or 1.8 percent.
• Humana's consolidated revenues for 2023 were $106.374 billion, compared to $92.870 billion in 2022.
• The company's pretax results for 2023 were $3.383 billion, compared to $3.568 billion in 2022.
• Humana's operating cash flows for 2023 were $3.981 billion, compared to $4.587 billion in 2022.

Sentiment

Score: 3

Explanation: The document conveys a negative sentiment due to the significant loss in Q4, lowered guidance for 2024, and the reduced long-term EPS target. While there are some positive aspects, the overall tone is one of disappointment and concern about the company's near-term performance.

Positives

• Humana achieved strong growth in its MA, Medicaid, and CenterWell businesses in 2023.
• The company is focused on driving sustainable value from productivity and administrative cost containment initiatives.
• Humana is expanding its multi-payer Primary Care platform and expects to add 30 to 50 incremental centers annually.
• The company is expanding its value-based home care models and expects to cover 3.4 million members by the end of 2024.
• Humana's digital pharmacy channel saw an 800 basis point increase in 2023, with continued positive momentum in 2024.
• The company anticipates double-digit growth in investment income in 2024.
• Humana has repurchased $400 million of shares to date in 2024, with a total of $1 billion planned for the year.

Negatives

• Humana reported a significant loss in Q4 2023 due to higher-than-expected medical costs.
• The company's initial 2024 EPS guidance is significantly lower than previously communicated.
• The company no longer believes its previously communicated $37 adjusted EPS target for 2025 is achievable.
• Humana experienced higher attrition during the AEP despite higher plan change activity.
• The company expects a net decline of approximately 650,000 PDP members in 2024.
• Humana anticipates a margin headwind in the Primary Care Organization in 2024 due to the initial phase-in of the v28 risk model revision.
• The company expects an increase of approximately $150 million in interest expense year over year.

Risks

• The company faces risks related to the design and pricing of its products, and the ability to manage medical costs.
• Humana's profitability could be materially adversely affected if its estimates of benefits expense are inadequate.
• The company's business may be materially adversely affected if it fails to effectively implement its operational and strategic initiatives.
• Humana is involved in various legal actions and disputes that could result in substantial monetary damages or changes in its business practices.
• Changes to the risk-adjustment model utilized by CMS could have a material adverse effect on the company's operating results.
• New laws or regulations could increase the company's cost of doing business and have a material adverse effect on Humana's results of operations.
• The company's failure to manage acquisitions, divestitures, and other significant transactions successfully may have a material adverse effect on its results of operations.
• Humana faces significant competition in attracting and retaining talented employees.
• Changes in the prescription drug industry pricing benchmarks may adversely affect Humana's financial performance.
• Downgrades in Humana's debt ratings may adversely affect its business, results of operations, and financial condition.

Future Outlook

Humana anticipates $6 to $10 in Adjusted EPS growth in 2025, driven by MA pricing actions, earnings growth in other lines of business, and productivity and trend mitigation initiatives. The company expects to prioritize margin recovery over membership growth in the near term. The company expects the Medicare Advantage industry to experience high single digit growth in the mid-term, including 2024.

Management Comments

• We are disappointed with the impact of the late and unexpected development of higher trends on our 2023 results and 2024 outlook.
• Our confidence in the long-term attractiveness of this sector and our position within it has not changed.
• We believe the elevated MA medical costs are an industry dynamic, not specific to Humana.
• We intend to prioritize margin recovery over membership growth near-term.
• We have conviction that the strong core fundamentals and growth outlook for MA and value-based care remain intact.
• We are proud of the strong growth we achieved in our MA, Medicaid and CenterWell businesses in 2023.
• We believe it is prudent to assume the higher costs persist throughout 2024.
• We continue to believe our more prudent approach to 2024 MA pricing was appropriate.
• We remain well positioned to compete as an industry leader in the attractive MA market going forward.
• We will lean further into product and go-to-market strategies that best serve the unique needs of our consumers.
• We are focused on delivering price transparency through direct to consumer messaging with a digital first call to action.
• We will continue to consider the use of Accelerated Share Repurchase programs, as well as open market repurchases, to ensure we maximize value from these programs.

Industry Context

The Medicare Advantage sector is experiencing significant regulatory changes and unprecedented increases in medical cost trends. Humana believes these elevated medical costs are an industry-wide issue, not specific to the company. The company is adjusting its strategies to prioritize margin recovery over membership growth in the near term, reflecting a broader industry response to these challenges.

Comparison to Industry Standards

• Humana's 2024 individual Medicare Advantage membership growth of 1.8% is lower than the industry average, reflecting a more cautious approach to pricing.
• The company's 2023 and 2024 combined growth reflects a compound annual growth (CAGR) of 10 percent compared to 8 percent for the industry.
• For the 7-year period ending 2024, Humana estimates a CAGR of nearly 10 percent, as compared to the expected industry CAGR of 9 percent.
• Humana achieved the second highest Individual MA net membership growth in AEP across the industry.
• The company's mail order penetration rate in its pharmacy business is industry leading.
• Humana's Star ratings are industry leading, indicating a high level of quality in its Medicare Advantage plans.
• The company's consumer experience rankings are best in class, suggesting a strong focus on customer satisfaction.

Management Changes

Stakeholder Impact

• Shareholders will be negatively impacted by the lower earnings and reduced guidance.
• Employees may experience changes due to cost containment and productivity initiatives.
• Customers may see changes in benefits as the company adjusts to higher medical costs.
• Providers may be impacted by changes in contracting and payment models.
• The company's financial performance may impact its ability to invest in future growth and innovation.

Next Steps

• Humana will continue to analyze the emerging trends in medical costs and identify additional opportunities to mitigate the impacts.
• The company will refine its 2024 outlook throughout the year as additional clarity is available.
• Humana will prioritize margin recovery over membership growth in the near term.
• The company will lean further into product and go-to-market strategies that best serve the unique needs of its consumers.
• Humana will continue to expand its multi-payer Primary Care platform.
• The company will continue to implement new value-based care delivery and payment models.
• Humana will continue to focus on driving sustainable value from productivity and administrative cost containment initiatives.
• The company will provide an update on its 2025 outlook post bid finalization.

Key Dates

Keywords

Medicare Advantage, Medical Cost Trends, EPS, Healthcare, Insurance, CenterWell, Membership Growth, Financial Results, Guidance, Pharmacy, Home Health, Primary Care